Search results for "Musculoskeletal"

showing 10 items of 1714 documents

Bone mineral density of the calcaneus in 70??? to 81-yr-old male athletes and a population sample

1991

Bone mineral content (BMC/W) and density (BMD) were studied in 70- to 81-yr-old active male endurance-trained (long-distance runners, cross-country skiers, N = 67), strength-trained (throwers, weight-lifters, N = 14), and speed-trained (sprinters, jumpers, N = 16) athletes. A population sample of similar age (N = 42) served as a control group. The measurements were performed at the calcaneus by single-energy photon absorption. The endurance-trained athletes had higher bone width and depth, and the strength and speed-trained athletes higher bone depth than the control subjects. The three groups of athletes showed 19-28% higher BMC (g.cm-1) and BMC/W (g.cm-2) than the control group (P less th…

Bone mineralmedicine.medical_specialtyPopulation samplebiologyBone densityFree androgen indexAthletesbusiness.industryPhysical Therapy Sports Therapy and Rehabilitationmusculoskeletal systembiology.organism_classificationSurgeryEndocrinologySex hormone-binding globulinInternal medicinemedicinebiology.proteinOrthopedics and Sports MedicineCalcaneusbusinessTestosteroneMedicine & Science in Sports & Exercise
researchProduct

ASSOCIATION BETWEEN LOW BONE MINERAL DENSITY, METABOLIC SYNDROME AND SEX STEROIDS DEFICIENCY IN MEN.

2019

OBJECTIVE: To analyze the association between low bone mineral density (BMD), metabolic syndrome (MS) and sex hormones deficiency in men. METHODS: We included in this retrospective study 199 men with osteoporosis or osteopenia and 167 men with normal BMD as controls, aged between 55-85 years old. Patients’ evaluation included: medical history and physical examination, X-ray of thoracic and lumbar spine, measuring BMD at hip and lumbar spine, serum glucose and lipid profile, serum levels of total testosterone (tT), free testosterone (fT) and estradiol (E2). RESULTS: The results revealed a significant association between low BMD and MS (p=0.011). Vertebral fractures were more frequently assoc…

Bone mineralmusculoskeletal diseasesmedicine.medical_specialtymedicine.diagnostic_testEndocrine and Autonomic Systemsbusiness.industryEndocrine CareEndocrinology Diabetes and MetabolismOsteoporosisPhysical examinationmedicine.diseasemusculoskeletal systemOsteopeniaEndocrinologyEndocrinologyInternal medicinemedicineMetabolic syndromeLipid profilebusinessTestosteroneHormoneActa endocrinologica (Bucharest, Romania : 2005)
researchProduct

The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

2015

The CB1 cannabinoid receptor, the main molecular target of endocannabinoids and cannabis active components, is the most abundant G protein-coupled receptor in the mammalian brain. In particular, the CB1 receptor is highly expressed in the basal ganglia, mostly on terminals of medium-sized spiny neurons, where it plays a key neuromodulatory function. The CB1 receptor also confers neuroprotection in various experimental models of striatal damage. However, the assessment of the physiological relevance and therapeutic potential of the CB1 receptor in basal ganglia-related diseases is hampered, at least in part, by the lack of knowledge of the precise mechanism of CB1 receptor neuroprotective ac…

Brain-derived neurotrophic factormedicine.medical_specialtyCannabinoid receptormusculoskeletal neural and ocular physiologymedicine.medical_treatmentCell BiologyBiologyEndocannabinoid systemδ-opioid receptorEndocrinologynervous systemInternal medicinemedicinelipids (amino acids peptides and proteins)CannabinoidSignal transductionReceptorMolecular BiologyProtein kinase BNeuroscienceCell Death & Differentiation
researchProduct

Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociability.

2015

The endocannabinoid (eCB) system possesses neuromodulatory functions by influencing the release of various neurotransmitters, including γ-aminobutyric acid (GABA) and glutamate. A functional interaction between eCBs and the serotonergic system has already been suggested. Previously, we showed that cannabinoid type-1 (CB1) receptor mRNA and protein are localized in serotonergic neurons of the raphe nuclei, implying that the eCB system can modulate serotonergic functions. In order to substantiate the physiological role of the CB1 receptor in serotonergic neurons of the raphe nuclei, we generated serotonergic 5-hydroxytryptamine (5-HT) neuron-specific CB 1 receptor-deficient mice, using the Cr…

CB1 receptorCannabinoid receptormedicine.medical_treatmentCognitive NeuroscienceCre recombinaseBiologySerotonergiclcsh:RC321-571Behavioral Neurosciencemedicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchmusculoskeletal neural and ocular physiologyGlutamate receptorraphe nucleianxietyEndocannabinoid systemserotoninsociabilityNeuropsychology and Physiological Psychologynervous systemlipids (amino acids peptides and proteins)CannabinoidSerotoninRaphe nucleiNeurosciencepsychological phenomena and processesNeuroscienceFrontiers in behavioral neuroscience
researchProduct

Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon

2007

Abstract It is well accepted that endogenous cannabinoids and CB1 receptors are involved in the regulation of smooth muscle contractility and intestinal motility, through a mechanism mainly related to reduction of acetylcholine release from cholinergic nerve endings. Because, few data exist on a possible modulatory action of the cannabinoid agents on the non-adrenergic non-cholinergic (NANC) excitatory and inhibitory neurotransmission, the aim of the present study was to investigate the effects of cannabinoid drugs on the NANC responses elicited by electrical field stimulation (EFS) in the circular muscle of mouse proximal colon. Colonic contractions were monitored as changes in endoluminal…

CB1 receptorIndolesCannabinoid receptormedicine.medical_treatmentSynaptic TransmissionSettore BIO/09 - FisiologiaEnteric Nervous SystemReceptor Cannabinoid CB2Micechemistry.chemical_compoundPiperidinesReceptor Cannabinoid CB1Fatty acid amide hydrolaseCannabinoid receptor type 2musculoskeletal neural and ocular physiologyAnandamideSmooth muscle contractionRimonabantAgonistmedicine.medical_specialtyColonPolyunsaturated Alkamidesmedicine.drug_classMorpholinesNeuromuscular JunctionArachidonic AcidsIn Vitro TechniquesNaphthalenesTachykininsInternal medicineCannabinoid Receptor ModulatorsIntestinal motilitymedicineAnimalsCannabinoidReceptors TachykininPharmacologyDose-Response Relationship DrugCannabinoidsExcitatory Postsynaptic PotentialsNANC relaxationURB597Electric StimulationBenzoxazinesMice Inbred C57BLEndocrinologyInhibitory Postsynaptic PotentialschemistryPyrazolesNANC contractionCannabinoidGastrointestinal MotilityEndocannabinoidsPharmacological Research
researchProduct

Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methot…

1999

SUMMARYImmunosuppressive therapy with methotrexate (MTX) has been established as effective treatment for patients with rheumatoid arthritis. To analyse the therapeutic potential and mechanisms of action of MTX, we determined serum cytokine levels and cytokine production by splenic T cells and macrophages in untreated and MTX-treated mice. Furthermore, we assessed the role of MTX in a murine model of experimental arthritis induced by collagen type II (CIA). MTX reduced spontaneous and IL-15-induced tumour necrosis factor (TNF) production by splenic T cells but not by macrophages from healthy mice in vitro in a dose-dependent manner. In contrast, interferon-gamma (IFN-γ) production was less s…

CD4-Positive T-LymphocytesMalemusculoskeletal diseasesT-Lymphocytesmedicine.medical_treatmentImmunologyArthritisMice TransgenicSpleenInterferon-gammaMiceImmune systemAnimalsImmunology and AllergyMedicineheterocyclic compoundsInterferon gammaskin and connective tissue diseasesInterleukin 4Interleukin-15Mice KnockoutMice Inbred BALB CInterleukin-6Tumor Necrosis Factor-alphabusiness.industryMacrophagesOriginal ArticlesImmunotherapymedicine.diseaseArthritis ExperimentalMethotrexatemedicine.anatomical_structureCytokineMice Inbred DBAImmunologyCytokinesTumor necrosis factor alphaCollagenInterleukin-4businessImmunosuppressive AgentsSpleenmedicine.drug
researchProduct

A test of the effort equalization hypothesis in children with cerebral palsy who have an asymmetric gait.

2022

Healthy people can walk nearly effortlessly thanks to their instinctively adaptive gait patterns that tend to minimize metabolic energy consumption. However, the economy of gait is severely impaired in many neurological disorders such as stroke or cerebral palsy (CP). Moreover, self-selected asymmetry of impaired gait does not seem to unequivocally coincide with the minimal energy cost, suggesting the presence of other adaptive origins. Here, we used hemiparetic CP gait as a model to test the hypothesis that pathological asymmetric gait patterns are chosen to equalize the relative muscle efforts between the affected and unaffected limbs. We determined the relative muscle efforts for the ank…

CP-oireyhtymäMalePhysiologyKneesKnee JointsSkeletal Joints3123 Gynaecology and paediatricsSTRENGTHMedicine and Health Sciencesvoimantuotto (fysiologia)ChildMusculoskeletal SystemGaitFatigueMultidisciplinaryLOCOMOTIONCP-vammaisetQRliikuntarajoitteetAnkle JointskävelyBiomechanical PhenomenaaskeleetLegsMedicineFemalebiomekaniikkaAnatomyGait AnalysisWALKINGResearch ArticleAdolescentScienceeducationPOWERlapset (ikäryhmät)MOVEMENTSigns and SymptomsSpatio-Temporal AnalysisHumansKneeSPEEDMuscle SkeletalSkeletonBiological LocomotionCerebral PalsyAnklesBiology and Life SciencesasymmetriaBody LimbsJointsClinical MedicineAnklehuman activitiesPLoS ONE
researchProduct

Activin-A, myostatin and interleukin-6 in cancer associated cachexia

2017

Cachexia is a muscle wasting condition associated with multiple different chronic illnesses, such as cancer, diabetes and AIDS. In cancer, approximately 80% of patients with advanced disease have symptoms of muscle wasting, and around 25% of cancer mortality concerns cachexia. Elevated serum levels of different cytokines and TGF-β protein family members, such as Interleukin-6, Myostatin and Activin-A, have been observed in cachetic patients and test animals. However, the mechanistic role and the relative contribution of these molecules to muscle loss in the syndrome have not yet been fully elucidated. In this thesis, the gene-expression levels of Activin-A, Myostatin and Interleukin-6 was a…

CachexiamyostatiiniInterleukin-6interleukiinitaktiviini-aActivin-AsyöpätauditkakeksiaC2C12proteiinitMyostatinmusculoskeletal systemhormones hormone substitutes and hormone antagonists
researchProduct

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

2019

One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI-induced musculoskeletal AEs. Women eligible for upfront adjuvant endocrine therapy with letrozole were included in the PreFace study, a multicenter phase IV trial. During the first treatment year, they were asked to record musculoskeletal AEs monthly by answering questions regarding pain symptoms and rating the pain intensity on a numeric rating scale from 0 (no pain) to 10 (very strong pain). Pain values were compared using nonparametric statis…

Cancer Researchmedicine.medical_specialtyTime Factorsmedicine.drug_classMedizinBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerMusculoskeletal PainInternal medicinemedicineHumansIn patientAdverse effectAgedPain MeasurementEarly breast cancerAromatase inhibitorAromatase Inhibitorsbusiness.industryLetrozoleSignificant differenceMiddle Agedmedicine.diseaseArthralgiaPostmenopauseOncology030220 oncology & carcinogenesisJoint painLetrozoleFemalemedicine.symptombusinessmedicine.drugInternational Journal of Cancer
researchProduct

Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

2012

Allosteric modulation of G-protein–coupled receptors represents a key goal of current pharmacology. In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs. Here we show that the anti-inflammatory lipid lipoxin A 4 is an endogenous allosteric enhancer of the CB 1 cannabinoid receptor. Lipoxin A 4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB 1 receptor (vs. 3 H-SR141716A), and did not alter endocannabinoid metabolism (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating …

Cannabinoid receptorAllosteric regulationAnti-Inflammatory AgentsSpatial BehaviorEndogenyAmyloidogenic ProteinsMice TransgenicBiologyPharmacologyReceptors G-Protein-Coupled03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineReceptor Cannabinoid CB1In vivoMemoryCommentariesAnimalsReceptor030304 developmental biologyInflammationMice Knockout0303 health sciencesMultidisciplinarymusculoskeletal neural and ocular physiologyBrainAnandamideURB597Biological SciencesEndocannabinoid system3. Good healthLipoxinsMice Inbred C57BLKineticsNeuroprotective Agentschemistrynervous systemlipids (amino acids peptides and proteins)030217 neurology & neurosurgerypsychological phenomena and processesAllosteric SiteEndocannabinoidsProceedings of the National Academy of Sciences of the United States of America
researchProduct